Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Polatuzumab vedotin by Genentech USA for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
Polatuzumab vedotin is under clinical development by Genentech USA and currently in Phase III for B-Cell Non-Hodgkin Lymphoma. According to...
Data Insights
Polatuzumab vedotin by Genentech USA for T-Cell Lymphomas: Likelihood of Approval
Polatuzumab vedotin is under clinical development by Genentech USA and currently in Phase III for T-Cell Lymphomas. According to GlobalData,...